New hope for tough pancreatic cancer: targeted drug enters final testing
NCT ID NCT07262567
Summary
This study is testing whether a new targeted drug called GFH375 works better than standard chemotherapy for people with advanced pancreatic cancer that has a specific genetic change (KRAS G12D mutation) and has worsened after previous treatment. About 320 participants will be randomly assigned to receive either the new drug or their doctor's choice of chemotherapy. The main goals are to see if the new drug helps people live longer and keeps the cancer from growing for a longer time compared to chemotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.